Benefit from our broad, meaningful therapeutic area expertise
Our scientists have significant exposure to all major therapeutic areas. From a bioanalytical perspective, we see ourselves as therapeutic area agnostic when it comes to method development and validation. Similarly, we analyze drug compounds in diverse biological matrices with minimal adjustments to our equipment and processes irrespective of the therapeutic area. That said, we are increasingly focusing more on oncology to align our interests with our current and prospective sponsor demands. Here, our scientists see a tremendous opportunity for innovation and efficiency in the drug development process, leading to higher R&D productivity and ultimately increased access to life-saving/prolonging drugs for millions of patients. To that end, our team has excellent name recognition among all premier Oncology centers in the US including, Dana Farber, MD Anderson, Sarah Cannon, Sloan Kettering, Moffitt Cancer Center, Yale Cancer Center, etc. For your reference, please find below a select list of our non-proprietary/approved oncology drugs with bioanalytical methods in-house. Understand, we are an oncology-focused bioanalytical lab that has worked on a much broader list of proprietary and in-development cancer-related drug compounds that we aren’t able to disclose at this time due to our confidentiality agreements. Additionally, we are reasonably confident towards developing/validating method within 4-8 weeks at a high value to our sponsors for any other oncology drug that might be of your interest.
Drug Name
- 5-Fluorouracil
- Anastrozole
- Aprepitant
- Bendamustine
- Bevacizumab
- Bicalutamide
- Brivanib
- Capecitabine
- Copanlisib
- Dacarbazine
- Doxorubicin
- Duvelisib
- Exemestane
- Gefitinib
- Gimeracil
- Ibrutinib
- Irinotecan
- Letrozole
- Niraparib
- Paclitaxel
- Palbociclib
- Pemetrexed
- Regorafenib
- Romidepsin
- Ruxolitinib
- SN-38
- Sorafenib
- Tamoxifen
- Tegafur
- Triptolide
- Venetoclax
- Vinorelbine